In a phase 2 multicenter randomized placebo-controlled study for psoriasis patients, treatment with a RIPK1 inhibitor improved the severity of plaque lesions compared with placebo without any severe drug-related adverse effects52. The gene discussed is RIPK1; the disease is psoriasis.